My colleagues and I are studying two other closely related proteins that regulate p53 by marking it for destruction when it's no longer needed. These proteins, called MDM2 and MDMX, become ...

However, loss of p53 tumour-suppressor activity can also occur through amplification of MDM2. As MDM2 is a negative regulator of p53, this promotes p53 degradation and inhibits p53 tumour ...

Western blot assays were performed to identify the presence of p53, phospho-p53, and murine double minute 2 (MDM2) isoforms in plasma samples. Densitometric analysis was used to determine the ...

enhancing MDM2 transcription independent of p53. Researchers from the University of Houston and Baylor College of Medicine presented preclinical data for MA-242, a dual inhibitor of MDM2 and NFAT1, ...

A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery and Interventional Science at University College London has systematically ...

A United States-based Nigerian doctoral researcher in systems biology and immunology, Prosper Chukwuemeka, is advancing cancer research by combining computational tools with biology.

It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein ...

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...

Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage.